Fierce Pharma Asia—GSK, Merck ADCs’ trial wins; AZ’s $1.5B EGFR buy; Biotechs’ new patent tricks

Antibody-drug conjugates from Kelun-Biotech and Hansoh Pharma, respectively partnered with Merck & Co. and GSK, delivered positive phase 3 readouts in China. | ADCs from Kelun-Biotech and Hansoh Pharma, respectively partnered with Merck and GSK, delivered positive phase 3 readouts. AstraZeneca reached out to its spinout Dizal for an EGFR lung cancer med. Biotechs are growing protective of their intellectual property and business intelligence. And more.